Evaluating intermediate endpoints (IE) for overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI): An IMDC study.

被引：0

作者：

Saliby, Renee Maria

Xie, Wanling

Wells, J. Connor

Saad, Eddy

Eid, Marc

Labaki, Chris

Semaan, Karl

Ferrier, Evan

Lemelin, Audreylie

Suarez, Cristina

Ruiz-Morales, Jose Manuel

Powles, Thomas

Wood, Lori

Ebrahimi, Hedyeh

de Velasco, Guillermo

Takemura, Kosuke null

Agarwal, Neeraj

Braun, David A.

Heng, Daniel Yick Chin

Choueiri, Toni K.

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Dana Farber Canc Inst, Dept Data Sci, Boston, MA USA

[3] BC Canc Agcy, Calgary, AB, Canada

[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[5] Tom Baker Canc Clin, Calgary, AB, Canada

[6] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain

[7] Med Sur SAB CV, Toriello Guerra, DF, Mexico

[8] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England

[9] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada

[10] City Hope Comprehens Canc Ctr, Duarte, CA USA

[11] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[12] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

[13] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[14] Yale Univ, New Haven, CT USA

[15] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[16] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

261-492-3532-2370-7650-2700; 283-2494-9200; 261-566-9718-9794; 613-4678-146-485; 613-135-2370-7646-2344; 261-566-9690; 6; 2; 1808; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.400

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：400 / 400

页数：1

共 50 条

[21] Elevated serum DC-HIL is associated with poor response to immune checkpoint inhibitors (ICI) in metastatic renal cell carcinoma (mRCC)
Chung, Jin-Sung
Ramani, Vijay
Cruz, Ponciano D.
Hammers, Hans J.
Ariizumi, Kiyoshi
CANCER RESEARCH, 2022, 82 (12)
[22] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
Zhu, Jason
Pabla, Sarabjot
Labriola, Matthew
Gupta, Rajan T.
McCall, Shannon
George, Daniel J.
Dressman, Devin
Glenn, Sean T.
Nesline, Mary
George, Saby
Morrison, Carl
Zhang, Tian
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[23] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
Zhu, Jason
Pabla, Sarabjot
Labriola, Matthew
Gupta, Rajan T.
McCall, Shannon
George, Daniel J.
Dressman, Devin
Glenn, Sean
Nesline, Mary
George, Saby
Morrison, Carl
Zhang, Tian
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[24] Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
Zhu, Jason
Pabla, Sarabjot
Labriola, Matthew
Gupta, Rajan T.
McCall, Shannon
George, Daniel J.
Dressman, Devin
Glenn, Sean
George, Saby
Morrison, Carl
Zhang, Tian
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[25] Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) - a validation study
Pond, G. R.
Dietrich, M.
Gruenwald, V.
ANNALS OF ONCOLOGY, 2016, 27
[26] Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis
Bakouny, Ziad
Xie, Wanling
Dudani, Shaan
Wells, Connor
Gan, Chun Loo
Donskov, Frede
Shapiro, Julia
Davis, Ian D.
Parnis, Francis
Ravi, Praful
Steinharter, John A.
Agarwal, Neeraj
Alva, Ajjai Shivaram
Wood, Lori
Kapoor, Anil
Morales, Jose Manuel Ruiz
Kollmannsberger, Christian K.
Beuselinck, Benoit
Heng, Daniel Yick Chin
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[27] Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI)
Brown, Jacqueline T.
Liu, Yuan
Martini, Dylan J.
Shabto, Julie M.
Hitron, Elise
Russler, Greta
Caulfield, Sarah
Yantorni, Lauren Beth
Joshi, Shreyas S.
Kissick, Haydn
Ogan, Kenneth
Carthon, Bradley Curtis
Kucuk, Omer
Harris, Wayne
Master, Viraj A.
Bilen, Mehmet Asim
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[28] Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.
Ravi, Praful
Mantia, Charlene
Su, Christopher
Sorenson, Karl
Rathi, Nityam
Bakouny, Ziad
Agarwal, Neeraj
Costello, Brian Addis
McKay, Rana R.
Narayan, Vivek
Alva, Ajjai Shivaram
McGregor, Bradley Alexander
Gao, Xin
McDermott, David F.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.
De Vries-Brilland, Manon
Gross-Goupil, Marine
Boughalem, Elouen
Beuselinck, Benoit
Thibault, Constance
Chevreau, Christine
Ladoire, Sylvain
Barthelemy, Philippe
Negrier, Sylvie
Borchiellini, Delphine
Huillard, Olivier
Geoffrois, Lionnel
Gravis, Gwenaelle
Saldana, Carolina
Thiery-Vuillemin, Antoine
Seegers, Valerie
Escudier, Bernard
Ravaud, Alain
Albiges, Laurence
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[30] Association between biopsychosocial distress (BPSD) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
Bergerot, C. D.
Clark, K. L.
Ashing, K. T.
Almeida, L.
Bergerot, P. G.
Obenchain, R.
Dizman, N.
Hsu, J.
Maia, M. C.
Philip, E.
Loscalzo, M.
Pal, S. K.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →